Jon A. Olson
Impact in
- Genetics top 2%
- Glioma Diagnosis and Treatment
- Infectious Diseases top 5%
- Antifungal resistance and susceptibility
Papers in
-
- Antifungal resistance and susceptibility 12
-
- Fungal Infections and Studies 6
- Nail Diseases and Treatments 3
- Co-authors
- Jill Adler‐Moore (14 shared papers)Richard T. Proffitt (9 shared papers)Julie Schwartz (5 shared papers)Gerard M. Jensen (3 shared papers)Peter J. Smith (3 shared papers)Megan Denise Lenardon (1 shared paper)Arturo Casadevall (1 shared paper)Louise A. Walker (1 shared paper)
- Journals
- Antimicrobial Agents and Chemotherapy (5 papers)Medical Mycology (2 papers)Journal of Antimicrobial Chemotherapy (2 papers)mBio (1 paper)Vaccine (1 paper)
- Partner nations
- United StatesAustraliaNetherlands
In The Last Decade
Jon A. Olson
18 papers receiving 1.6k citations
Jon A. Olson's Hit Papers
Peers
Comparison fields: 5 of 101
- Genetics 586
- Infectious Diseases 363
- Immunology 311
- Oncology 349
- Cancer Research 142
Countries citing papers authored by Jon A. Olson
This map shows the geographic impact of Jon A. Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon A. Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon A. Olson more than expected).
Fields of papers citing papers by Jon A. Olson
This network shows the impact of papers produced by Jon A. Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon A. Olson. The network helps show where Jon A. Olson may publish in the future.
Co-authors
The 25 scholars most cited alongside Jon A. Olson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial Hit paper breakdown → | 2017 | 930 |
| 2 | 2018 | 153 | |
| 3 | 2006 | 78 | |
| 4 | 1986 | 75 | |
| 5 | 2005 | 71 | |
| 6 | 2007 | 67 | |
| 7 | 2006 | 60 | |
| 8 | 2007 | 55 | |
| 9 | 2014 | 32 | |
| 10 | 2004 | 28 | |
| 11 | 2010 | 26 | |
| 12 | 2017 | 16 | |
| 13 | 2010 | 15 | |
| 14 | 2011 | 12 | |
| 15 | 2020 | 12 | |
| 16 | 2022 | 10 | |
| 17 | 2014 | 9 | |
| 18 | 2009 | 1 | |
| 19 | 2013 | 0 |
About Jon A. Olson
Jon A. Olson is a scholar working on Infectious Diseases, Epidemiology, Pharmacology, Immunology and Allergy and Microbiology, having authored 19 papers that have together received 1.6k indexed citations. Recurring topics across this work include Antifungal resistance and susceptibility (12 papers), Fungal Infections and Studies (6 papers), Asthma and respiratory diseases (3 papers), Nail Diseases and Treatments (3 papers), Respiratory and Cough-Related Research (2 papers), Helminth infection and control (2 papers), Antimicrobial Peptides and Activities (2 papers) and Fungal Biology and Applications (2 papers). The work is most often cited by research in Genetics (586 citations), Infectious Diseases (363 citations), Immunology (311 citations), Oncology (349 citations) and Cancer Research (142 citations). Jon A. Olson has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include Jill Adler‐Moore, Richard T. Proffitt, Julie Schwartz, Gerard M. Jensen, Peter J. Smith, Megan Denise Lenardon, Arturo Casadevall, Louise A. Walker, Julie M. Wolf and Prashant Sood. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Medical Mycology, Journal of Antimicrobial Chemotherapy, mBio and Vaccine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.